Osterziel K J, Dietz R
Franz-Volhard-Klinik, Virchowklinikum, Humboldt Universität zu Berlin, Germany.
J Cardiovasc Pharmacol. 1996;27 Suppl 2:S25-30. doi: 10.1097/00005344-199600002-00006.
A total of 35 patients in sinus rhythm and with mild-to-moderate congestive heart failure (CHF) (NYHA II-III) aged 53 (+/- 3) years were examined before therapy with angiotensin-converting enzyme (ACE) inhibitors. Of these patients, 16 were reexamined after therapy with ACE inhibitors for 17 +/- 3 days. The relation of hemodynamic alterations to vagal tone was assessed and the influence of parasympathetic (baroreflex activation) tone on survival was evaluated. Only hemodynamic responders to ACE inhibition showed a significant increase of vagal tone from 1.4 +/- 0.4 to 3.6 +/- 1.2 ms/mm Hg (p < 0.01). The magnitude of increase of vagal tone was dependent on the baseline level. All 35 patients were discharged on ACE inhibitors and were followed for 56 months or longer. We compared patients whose hearts survived (20 patients) with those whose hearts did not (15 patients). Twelve patients died and three underwent cardiac transplantation. The two groups differed (p < 0.05) in terms of mean arterial blood pressure (98 +/- 3 vs. 90 +/- 3 mm Hg), heart rate (82 +/- 2 vs. 93 +/- 4 beats/min), and mean pulmonary artery pressure (24 +/- 3 vs. 35 +/- 2 mm Hg). Cardiac index, stroke volume index, and right atrial pressures were not different. Heart survivors had lower (p < 0.05) renin values (3.6 +/- 0.8 vs. 9.0 +/- 3.6 Ang-I/ml/h) but norepinephrine values at baseline were not different. Baroreflex sensitivity was lower (p < 0.02) in survivors than in nonsurvivors (1.3 +/- 0.2 vs. 2.3 +/- 0.3 ms/mm Hg). We then calculated the mortality risk in relation to baroreflex sensitivity at the median BS of 1.6 ms/mm Hg. Survival was different (p < 0.004) between the resulting two groups: 2 of 15 subjects (13%) with high baroreflex sensitivity died, and 13 of 20 patients (65%) whose baroreflex sensitivity was less than 1.6 ms/mm Hg died. When systemic blood pressure, pulmonary artery pressure, stroke volume index, plasma norepinephrine concentrations, and baroreflex sensitivity were entered into a Cox proportional hazards regression, only systolic blood pressure and plasma norepinephrine values predicted survival (p < 0.001). We concluded that high vagal tone is correlated with a good prognosis in patients with CHF. ACE inhibitor therapy can increase the vagal tone significantly. This may alter the incidence of sudden cardiac death and thereby improve prognosis.
对35例年龄为53(±3)岁、处于窦性心律且患有轻至中度充血性心力衰竭(CHF)(纽约心脏协会II - III级)的患者在使用血管紧张素转换酶(ACE)抑制剂治疗前进行了检查。在这些患者中,16例在接受ACE抑制剂治疗17±3天后接受了复查。评估了血流动力学改变与迷走神经张力的关系,并评估了副交感神经(压力反射激活)张力对生存率的影响。只有对ACE抑制有血流动力学反应的患者迷走神经张力从1.4±0.4显著增加至3.6±1.2毫秒/毫米汞柱(p<0.01)。迷走神经张力增加的幅度取决于基线水平。所有35例患者均出院时服用ACE抑制剂,并随访了56个月或更长时间。我们比较了心脏存活的患者(20例)和心脏未存活的患者(15例)。12例患者死亡,3例接受了心脏移植。两组在平均动脉血压(98±3与90±3毫米汞柱)、心率(82±2与93±4次/分钟)和平均肺动脉压(24±3与35±2毫米汞柱)方面存在差异(p<0.05)。心脏指数(CI)、每搏量指数(SVI)和右心房压力无差异。心脏存活者的肾素值较低(p<0.05)(3.6±0.8与9.0±3.6血管紧张素I/毫升/小时),但基线时去甲肾上腺素值无差异。存活者的压力反射敏感性低于未存活者(p<0.02)(1.3±0.2与2.3±0.3毫秒/毫米汞柱)。然后我们计算了与压力反射敏感性(中位数为1.6毫秒/毫米汞柱)相关的死亡风险。结果两组的生存率不同(p<0.004):15例压力反射敏感性高的受试者中有2例(13%)死亡,20例压力反射敏感性低于1.6毫秒/毫米汞柱的患者中有13例(65%)死亡。当将收缩压、肺动脉压、每搏量指数、血浆去甲肾上腺素浓度和压力反射敏感性纳入Cox比例风险回归分析时,只有收缩压和血浆去甲肾上腺素值可预测生存率(p<0.001)。我们得出结论,高迷走神经张力与CHF患者的良好预后相关。ACE抑制剂治疗可显著增加迷走神经张力。这可能会改变心源性猝死的发生率,从而改善预后。